A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Inclusion Criteria

• Age 18 years or older
• Diagnosed CD20+ B- chronic lymphocytic leukemia (CLL) according to National Cancer Institute (NCI) criteria
• Active disease meeting at least 1 of the International Workshop on CLL (IWCLL) 2008 criteria for treatment
• Refractory CLL (i.e. treatment failure or progression during treatment or within 6 months after the last treatment) or relapse CLL (i.e. participants who met criteria for CR or PR, but progressed beyond 6 months post-treatment)
• At least 1 prior purine analogue or bendamustine containing therapy
• Life expectancy greater than (>) 6 months
• Use of effective contraception as described in the study protocol

Exclusion Criteria

• Prior Alogenic Bone Marrow Transplant
• Greater than or equal to (>/=) 3 previous lines of chemotherapy and/or immunotherapy for the CLL
• Previous obinutuzumab-containing regimen
• Treatment failure or progression within 6 months of bendamustine-containing regimen
• Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL; Richter's transformation) Patients with prolymphocytic transformation cannot entry the study either
• Active haemolytic anaemia
• Inadequate liver function
• History of other malignancy which could affect compliance with the protocol or interpretation of results. Patients with a history of malignancy that has been treated but not with curative intent will be excluded, unless the malignancy has been in remission without treatment for >/= 2 years prior to enrolment. Patients with a history of adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low grade, early stage localized prostate cancer treated surgically with curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent are eligible
• Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease or pulmonary disease
• Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis
• Regular treatment with corticosteroids during the 4 weeks prior to study start, unless administered for another condition at a dose equivalent to less than or equal to (</=) 30 milligrams per day (mg/day) prednisone
• Known active infection or any infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to study start
• Patients with HIV, human T cell leukemia virus 1 (HTLV-1), hepatitis B or hepatitis C
• Pregnancy or breast-feeding
• Vaccination with a live vaccine within 4 weeks prior to baseline visit
• Receipt of any other study drug within 4 weeks prior to study start